A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab in Patients With Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying Therapy or the Lowest Strength of Statin

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab in Patients With Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying Therapy or the Lowest Strength of Statin

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Jul 2017

At a glance

  • Drugs Alirocumab (Primary) ; Atorvastatin; Bezafibrate; Ezetimibe; Fenofibrate
  • Indications Hypercholesterolaemia
  • Focus Therapeutic Use
  • Acronyms ODYSSEY-NIPPON
  • Sponsors Sanofi
  • Most Recent Events

    • 09 Jul 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Jan 2018.
    • 10 Jun 2017 Biomarkers information updated
    • 20 Apr 2017 Planned End Date changed from 1 Mar 2018 to 1 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top